Bol'nica Irkutskogo nauchnogo centra SO RAN
Russian Federation
Russian Federation
Russian Federation
Irkutsk Scientific Center SB RAS (otdel mediko-biologicheskih issledovaniy i tehnologiy, zaveduyuschiy)
Irkutsk, Irkutsk region, Russian Federation
Purpose of the study. To test the functional associations of polymorphic variants of genes in the regulation of blood pressure and vascular tone in employees of the ISC SB RAS. Materials and methods. The study involved patients, employees of the ISC SB RAS, being under care of the outpatient clinic of the Hospital of the ISC SB RAS. During routine laboratory testing the patients were taken 2 ml of blood for genetic analysis and further molecular genetic study on “Hypertension”, “Endothelial dysfunction”, “Pharmacogenetics”, “Inflammatory response” panels. Results. In the analysis of 12 genes coding for key proteins of hormonal enzyme blood pressure regulation systems, polymorphism of CYP11B2 showed statistically significant correlation with the presence of arterial hypertension, which makes its further study promising. The presence of allele C showed protective significance in relation to the development of hypertension with OR = 0,247. When checking associations of functional polymorphic variants of genes, the products of which are involved in the regulation of vascular tone, with hypertension in patients younger than 50 years old we found association of T/T rs5443GNB3 genotype with the debut of hypertensive disease under the age of 50. The data obtained allow the doctor to choose the most personalized and effective safe drug from certain groups, as well as its dose for employees having passed molecular genetic testing. These data can reveal predisposition to the most widespread and socially significant diseases in the surveyed subjects and provide specific personalized recommendations for the prevention of these diseases.
personalized medicine, cardiovascular disease, hypertension, genetic predisposition, pharmacogenetics, r esearch of ficers
Сердечно-сосудистые заболевания (ССЗ) являются основной причиной смерти во всём мире: ни от какой другой причины ежегодно не умирает столько людей, сколько от ССЗ [1]: ежегодно от ССЗ умирают 17,3 млн человек, что составляет 30 % всех случаев смерти в мире [2]. Из этого числа 7,3 млн человек умирают от ишемической болезни сердца (ИБС) и 6,2 млн – в результате инсульта [2, 3]. К 2030 г. около 23,3 млн человек умрут от ССЗ – главным образом, от болезней сердца и инсульта, которые, по прогнозам, останутся единственными основными причинами смерти [1, 4].
1. World Health Organization. World report on noninfectious diseases. – Geneva, 2010.
2. Mensah G.A., Ryan U.S., Cooper W.C., Engelgau M.M. et al. Vascular endothelium summary statement II: Cardiovascular disease prevention and control // Vascular Pharmacology. – 2007. – Vol. 46. – P. 318–320.
3. World Health Organization. Global atlas on cardiovascular disease prevention and control. – Geneva, 2011.
4. Mathers C.D., Loncar D. Projections of global mortality and burden of disease from 2002 to 2030 // PLoS Med. – 2006. – Vol. 3 (11). – P. 442.
5. Lifshic G.I., Belevanceva A.V., Ermolenko N.A., Koh N.V. Geneticheskaya karta zdorov'ya: Uchebno-metodicheskoe posobie. – Novosibirsk? 2010. – 78 s.
6. FDA/ Guidance for industry. Pharmacogenomics data submissions [Elektronnyy resurs]. – 2005 – Rezhim dostupa: https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm079849.pdf
7. Lifshic G.I., Danilkina S.T., Gus'kova E.V., Voronina E.N. i dr. Associaciya genov, kodiruyuschih belki gemostaza, s parametrami perifericheskogo gemostaza i predraspolozhennost'yu k aterotrombozam u pacientov s serdechno-sosudistymi zabolevaniyami // Kardiovaskulyarnaya terapiya i profilaktika. – 2011. – № 4. – S. 90–96.
8. Aparcin K.A., Grigor'ev E.G. Perspektivy translyacionnyh issledovaniy v Irkutskom nauchnom centre // Aktual'nye problemy hirurgicheskoy gepatologii: Sb. mater. – 2012. – 250 s.
9. Kireeva V.V., Aparcin K.A. Farmakogeneticheskoe testirovanie kak metod issledovaniy translyacionnoy mediciny // Nauka v sovremennom informacionnom obschestve: Mater. mezhdunar. nauch.-prakt. konf. – M., 2013. – S. 80–82.
10. Kireeva V.V., Lifshic G.I., Aparcin K.A. Translyacionnye issledovaniya faktorov tolerantnosti k povrezhdeniyu sosudistoy stenki i ee regeneratornogo potenciala // Nauka v sovremennom informacionnom obschestve: Mater. mezhdunar. nauch.-prakt. konf. (North Charleston, USA, 28–29 avgusta 2014 g.). – 2014. – S. 42–44.
11. International Consortium for Blood Pressure Genome-Wide Association Studies et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk // Nature. – 2011. – Vol. 478. – P. 103–109.
12. Koh N.V., Lifshic G.I. Geneticheskie aspekty v etiologii i farmakoterapii arterial'noy gipertonii // Spravochnik zaveduyuschego KDL. – 2015. – № 5. – S. 13–21.
13. Kireeva V.V., Koh N.V., Lifshic G.I., Aparcin K.A. Disfunkciya endoteliya kak kraeugol'nyy kamen' serdechno-sosudistyh sobytiy: molekulyarno- i farmakogeneticheskie aspekty // Rossiyskiy kardiologicheskiy zhurnal. – 2014. – № 10 (114). – S. 64–68.
14. Dzugkoev S.G., Mozhaeva I.V., Takoeva E.A. i dr. Mehanizmy razvitiya endotelial'noy disfunkcii i perspektivy korrekcii // Fundamental'nye issledovaniya. – 2014. – № 4. –S. 198–204.
15. Lizogub V.G., Kucko N.V. Ishemicheskaya bolezn' serdca // Zdorov'e. – 2007. – № 4. – S. 7–14.
16. Nikolaeva A.A., Nikolaev K.Yu., Lifshic G.I. Mikrocirkulyatornaya sosudistaya reaktivnost' k deystvuyuschim cherez endoteliy vazoaktivnym veschestvam pri arterial'noy gipertonii // Sibirskiy nauchnyy medicinskiy zhurnal – 2011. – № 31 (5). – S. 48–52.
17. Nikolaev K.Yu., Lifshic G.I., Pronin V.S. Patofiziologicheskie aspekty vliyaniya tabakokureniya na mikrocirkulyaciyu // Vestnik NGU: Biologiya, Klinicheskaya medicina. – 2010. – № 8 (4). – S. 119–123.
18. Gicheva I.M., Nikolaeva A.A., Oteva E.A., Nikolaev K.Yu. Kurenie podrostkov i ih krovnyh rodstvennikov kak faktor riska serdechno-sosudistyh bolezney v molodom vozraste (semeynye aspekty) // Sibirskiy medicinskiy zhurnal. – 2011. – № 26 (2). – S. 62–66.
19. Lifshic G.I., Filipenko M.L., Shevela A.I. Personalizirovannaya medicina. Lechit' ne bolezn', a bol'nogo // Nauka iz pervyh ruk. – 2012. – № 2 (44). – S. 58–65.
20. Zelenskaya E.M., Koh N.V., Kireeva V.V., Aparcin K.A. Associaciya gena CYP11B2 s riskom razvitiya gipertonicheskoy bolezni i aterotromboticheskih oslozhneniy // Kardiovaskulyarnaya terapiya i profilaktika. –2016. – № 15 (3). – S. 63–68.
21. Baranov V.S. Genom cheloveka, «nedostayuschaya» nasledstvennost' i geneticheskiy pasport // Medicinskaya genetika. – 2011. – № 9 (111). – S. 3.
22. Kireeva V.V. Geneticheskaya predraspolozhennost' k arterial'noy gipertonii u sotrudnikov Irkutskogo nauchnogo centra // Fundamental'naya nauka i tehnologii – perspektivnye razrabotki: Mater. VII mezhdunar. nauch.-prakt. konf. – 2015. – S. 79–81.
23. Koh N.V., Kireeva V.V., Slepuhina A.A. Arterial'naya gipertoniya: molekulyarno-geneticheskie farmakogeneticheskie podhody // V kn.: Novye aspekty etiopatogeneza, diagnostiki i lecheniya arterial'nyh i venoznyh trombozov. – Novosibirsk, 2016. – S. 110–122.
24. Herrera M.D., Mingorance C., Rodriguez-Rodriguez R. et al. Endothelial dysfunction and aging: An update // Ageing Research Reviews. – 2010 – Vol. 9. – P. 142–152.
25. Lam C.S.P., Brutsaert D.L. Endothelial dysfunction. A pathophysiologic factor in heart failure with preserved ejection fraction // JACC. – 2012. – Vol. 60. – P. 1787–1789.
